You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

253 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Feb 2025
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue, 
Skin, 
Melanoma
Intent: Palliative
Jun 2025
Regimen
Cancer Type:
Breast, 
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
ODB - General Benefit
    exemestane
Aug 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
May 2020
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
May 2020
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Unresectable or metastatic/recurrent Gastrointestinal Stromal Tumour, with specific criteria
Oct 2020
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    letrozole
Aug 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
    leuprolide - long-acting formulation
May 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
    leuprolide - long-acting formulation
ODB - General Benefit
    bicalutamide
May 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Aug 2025
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
May 2020
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
May 2020

Pages